Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis
- First Posted Date
- 2021-09-29
- Last Posted Date
- 2024-08-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 146
- Registration Number
- NCT05061693
- Locations
- 🇺🇸
Investigative Site US016, Miami, Florida, United States
🇵🇱Investigative Site PL004, Torun, Poland
🇺🇸Investigative Site US010, Phoenix, Arizona, United States
Study of Ruxolitinib Cream in Children With Atopic Dermatitis
- First Posted Date
- 2021-09-05
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 29
- Registration Number
- NCT05034822
- Locations
- 🇺🇸
Desert Sky Dermatology, Gilbert, Arizona, United States
🇺🇸Ohio Pediatric Research Association, Dayton, Ohio, United States
🇺🇸Advanced Medical Research Pc, Sandy Springs, Georgia, United States
Study of INCA 0186 in Subjects With Advanced Solid Tumors
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)Advanced Solid TumorsGastrointestinal (GI) Malignancies
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 57
- Registration Number
- NCT04989387
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇧🇪Universitair Ziekenhuis Antwerpen (Uza), Edegem, Belgium
🇳🇱University Medical Center Groningen, Groningen, Netherlands
realMIND: Observational Study on Safety and Effectiveness of Tafasitamab in Combination With Lenalidomide in Patients With Relapsed or Refractory DLBCL
- First Posted Date
- 2021-07-29
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 100
- Registration Number
- NCT04981795
- Locations
- 🇺🇸
University of California, Irvine Medical Center, Orange, California, United States
🇺🇸Alabama Oncology, Birmingham, Alabama, United States
🇺🇸Clearview Cancer Institute, Huntsville, Alabama, United States
The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
- Conditions
- Advanced Malignancies
- Interventions
- First Posted Date
- 2021-07-02
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT04949191
- Locations
- 🇺🇸
Virginia Cancer Specialists, Pc, Fairfax, Virginia, United States
🇺🇸Oncology Specialists of Charlotte, Charlotte, North Carolina, United States
🇮🇹Istituto Nazionale Tumori Regina Elena Irccs, Rome, Italy
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children With Atopic Dermatitis (TRuE-AD3)
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2025-03-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 330
- Registration Number
- NCT04921969
- Locations
- 🇺🇸
Ohio Pediatric Research Association, Dayton, Ohio, United States
🇺🇸Velocity Clinical Research Grants Pass Clinical Research Institute of Southern Oregon Pc, Grants Pass, Oregon, United States
🇺🇸Penn State Milton S. Hershey Medical Center, Hershey, Pennsylvania, United States
A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)
- First Posted Date
- 2021-05-21
- Last Posted Date
- 2024-05-02
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT04896385
- Locations
- 🇺🇸
George Washington Medical Faculty Associates, Washington, District of Columbia, United States
🇺🇸Suny Downstate Medical Center, Brooklyn, New York, United States
🇺🇸Mount Sinai Hospital, New York, New York, United States
A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma
- Conditions
- Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-04-29
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT04849715
The Purpose of the Study is to Evaluate the Effect of Ruxolitinib Cream on Itch in Participants With Atopic Dermatitis
- First Posted Date
- 2021-04-09
- Last Posted Date
- 2023-10-31
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 49
- Registration Number
- NCT04839380
- Locations
- 🇨🇦
Innovaderm Research Inc., Montreal, Quebec, Canada
🇨🇦Innovoderm Research, Montreal, Quebec, Canada
To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 48
- Registration Number
- NCT04831996
- Locations
- 🇺🇸
Orange County Research Center, Tustin, California, United States
🇺🇸Clinical Pharmacology of Miami, Hialeah, Florida, United States
🇺🇸Prism Research, Saint Paul, Minnesota, United States